Skip to main content
AMRX
NASDAQ Life Sciences

Co-founder Tushar Patel's stake rises to 17.6% after Kashiv Acquisition

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$17.328
Mkt Cap
$5.64B
52W Low
$8.82
52W High
$19.26
52W Position info
96% above low
Off High info
10% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

AMRX sits 96% above its 52-week low of $8.82.

Summary

Amneal co-founder Tushar Patel's beneficial ownership rose to 17.6% after his entity received 12.76 million shares in the Kashiv BioSciences acquisition, which closed August 10, 2026.


Key Events · Ownership and Investor Activity · AMRX

  • Patel's Stake Rises to 17.6%

    Tushar Patel's beneficial ownership increased to 61,341,678 shares (17.6% of Class A common stock) after his entity Rock Nola received 12,763,469 shares in the Kashiv Acquisition.

  • Kashiv Acquisition Closes

    The acquisition of Kashiv BioSciences closed on August 10, 2026, with Amneal paying $375 million in cash and issuing 28,942,098 shares to sellers, including Rock Nola.

  • Ownership Consolidation

    Patel's increased stake reflects his role as a seller in the acquisition, not a new purchase, consolidating his position as a major shareholder.


Analysis · AMRX · Life Sciences

Tushar Patel, co-founder of Amneal Pharmaceuticals, increased his beneficial ownership to 17.6% (61.3 million shares) after his entity Rock Nola received 12.76 million shares as part of the Kashiv BioSciences acquisition. The deal closed on August 10, 2026, with Amneal paying $375 million in cash and issuing 28.9 million shares to sellers. Patel's increased stake reflects his role as a seller in the acquisition, not a new purchase, and consolidates his position as a major shareholder.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AMRX was trading at $17.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.6B. The 52-week trading range was $8.82 to $19.26. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AMRX - Latest Insights

AMRX
Nov 17, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $21.12
Real-time Price: $21.12 info
Change: $0 (0%) info
Market Cap: $7.358B info
AMRX
Nov 09, 2026, 4:21 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $21.28
Real-time Price: $21.12 info
Change: -$0.160 (-0.75%) info
Market Cap: $7.358B info
AMRX
Nov 03, 2026, 6:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $20.23
Real-time Price: $21.12 info
Change: +$0.894 (+4%) info
Market Cap: $7.358B info
AMRX
Nov 03, 2026, 6:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $20.20
Real-time Price: $21.12 info
Change: +$0.920 (+5%) info
Market Cap: $7.358B info
AMRX
Oct 23, 2026, 4:05 PM EDT
Filing Type: 8-K/A
Importance Score:
8
Price at Filing: $20.38
Real-time Price: $21.12 info
Change: +$0.740 (+4%) info
Market Cap: $7.358B info